A multiplex platform for the identification of ovarian cancer biomarkers.

Citation data:

Clinical proteomics, ISSN: 1542-6416, Vol: 14, Issue: 1, Page: 34

Publication Year:
2017
Usage 16
Abstract Views 9
Full Text Views 6
Link-outs 1
Captures 10
Readers 10
Social Media 2
Tweets 2
PMID:
29051715
DOI:
10.1186/s12014-017-9169-6
Author(s):
Kristin L. M. Boylan; Kate Geschwind; Joseph S. Koopmeiners; Melissa A. Geller; Timothy K. Starr; Amy P. N. Skubitz
Publisher(s):
Springer Nature
Tags:
Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
article description
Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients.